REDDY-POMALIDOMIDE CAPSULE

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

POMALIDOMIDE

から入手可能:

DR REDDY'S LABORATORIES LTD

ATCコード:

L04AX06

INN（国際名）:

POMALIDOMIDE

投薬量:

4MG

医薬品形態:

CAPSULE

構図:

POMALIDOMIDE 4MG

投与経路:

ORAL

パッケージ内のユニット:

15G/50G

処方タイプ:

Prescription

製品概要:

Active ingredient group (AIG) number: 0155290004; AHFS:

認証ステータス:

APPROVED

承認日:

2023-02-20

製品の特徴

Page 1 of 59
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
REDDY-POMALIDOMIDE
Pomalidomide Capsules
Capsules, 1 mg, 2 mg, 3 mg and 4 mg, for oral use
Antineoplastic Agent
Immunomodulatory
Agent
ATC Code: L04AX06
Manufactured By:
Date of Initial Approval:
DR. REDDY’S LABORATORIES LTD.,
August 21, 2020
Bachupally - 500090 India
Imported and Distributed By:
Date of Revision:
DR. REDDY’S LABORATORIES CANADA INC.
December 7, 2022
Mississauga ON L4W 4Y1 Canada
Submission Control Number: 265686
Page 2 of 59
RECENT MAJOR LABEL CHANGES
7 Warnings and Precautions, Infections
08/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT
LISTED.
RECENT MAJOR LABEL
CHANGES.................................................................................2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................... 4
1
INDICATIONS
........................................................................................................................
4
1.1 Pediatrics
.............................................................................................................................
4
1.2
Geriatrics..............................................................................................................................
4
2 CONTRAINDICATIONS
........................................................................................................
4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................... 5
4 DOSAGE AND ADMINISTRATION
.....................................................................................
6
4.1 Dosing Considerations
.......................................................................................................
6
4.2 Recommended Dose and Dosage Adjustment
................................................................. 6
4.3 Administration
...............................................................................